Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors

Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis

(2014) Tetsuhide Ito et al.   JOURNAL OF GASTROENTEROLOGY

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

(2014) Martyn E. Caplin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial Data

(2013) Charles Ferté et al.   EUROPEAN UROLOGY

Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors

(2011) Jens Hasskarl et al.   Future Oncology

The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant

(2011) Irvin M. Modlin et al.   LANGENBECKS ARCHIVES OF SURGERY

Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors

(2010) Jonathan Strosberg   WORLD JOURNAL OF GASTROENTEROLOGY

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

(2009) Anja Rinke et al.   JOURNAL OF CLINICAL ONCOLOGY

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors

(2007) Tullio Florio   Frontiers in Bioscience-Landmark